Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.3152W HIGH $9.22
Volume
99.65 K
Value Traded
222.15 K
Short % Float
7.54%
Days to Cover
4.5
+28.83%Week
+25.94%1 Month
+51.2%3 Month
+225.81%6 Month
-99.87%5 Year
-99.92%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
13.26 M
EPS (TTM)
-22.01
P/E Ratio
-
Ent. Value
-15.45 M
Total Shares
2.63 M
Float Shares
2.38 M
Insiders
9.20%
Institutions
19.41%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
ADIL Catalyst Timeline
Dated clinical, regulatory and corporate events for Adial Pharmaceuticals, Inc
Catalyst Timeline
Dated clinical, regulatory & corporate events for Adial Pharmaceuticals, Inc
338Total events
12Upcoming
59Tier-1 (high impact)
2017 to 2028Coverage
Upcoming catalysts 2
Event history 50
●Corporate ApprovalCorporate
Stockholders approved conversion of Series A preferred stock from June 2026 Azora acquisition
●Management ChangeCorporate
New executive leadership team appointed, including CEO Matt Davidson
◆Management ChangeCorporate
Appointment of Matthew Davidson as chief development officer and Julie Saiki as executive vice president of strategy
▲Partnership / LicenseAD04FiledCorporate
Collaboration framework established with Molteni Farmaceutici for AD04 in Europe
Alcohol Use Disordersource ↗
▲Patent GrantedAD04FiledIP / Competition
International patent application published, expected to extend protection through at least 2045 if granted
Alcohol Use Disordersource ↗
●Composition Patent FiledAD04FiledIP / Competition
Filed new U.S. utility patent application for AD04 with Track One Prioritized examination
Alcohol Use Disordersource ↗
●NDA SubmissionAD04FiledRegulatory Filing
Submitted application to FDA Commissioner's National Priority Voucher Pilot Program for AD04
Alcohol Use Disordersource ↗
▲Manufacturing MilestoneAD04FiledCMC / Inspection
Successful completion of demonstration batch production for AD04
Alcohol Use Disordersource ↗
●Runway Guidance UpdateCorporate
Cash and cash equivalents $4.6M as of March 31, 2026; expected to fund operations into H2 2026
▲Partnership / LicenseAD04FiledCorporate
Exclusive collaboration framework with Molteni Farmaceutici for European commercialization of AD04
Alcohol Use Disordersource ↗
◆Oral PresentationPresentation
Adial Pharmaceuticals to present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
▲FDA Feedback ReceivedAD04FiledFDA Meeting
FDA policy direction may allow single pivotal trial for AD04
Alcohol Use Disordersource ↗
▲Composition Patent FiledAD04FiledIP / Competition
International PCT patent application for AD04 published
Alcohol Use Disordersource ↗
▲Patent GrantedAD04FiledIP / Competition
Publication of international patent application for AD04
Alcohol Use Disordersource ↗
▼Equity OfferingCorporate
Warrant inducement transaction for approximately $2.86 million in gross proceeds
▲End Of Phase 2 MeetingAD04FiledFDA Meeting
Successful End of Phase 2 meeting with FDA
Alcohol Use Disordersource ↗
▲End Of Phase 2 MeetingAD04FiledFDA Meeting
End of Phase 2 meeting with FDA for AD04
Alcohol Use Disordersource ↗
▲Patent GrantedAD04FiledIP / Competition
New patent filing for AD04 expected to extend market exclusivity to 2045
Alcohol Use Disordersource ↗
▲Partnership / LicenseAD04FiledCorporate
Partnership with Genomind for precision medicine testing solution
Alcohol Use Disordersource ↗
◆Trial InitiationAD04FiledTrial
Phase 3 trial expected to begin in late 2025
Alcohol Use Disordersource ↗
▲FDA Feedback ReceivedAD04FiledFDA Meeting
Receipt of final meeting minutes from FDA EOP2 meeting
Alcohol Use Disordersource ↗
▲Patent GrantedAD04FiledIP / Competition
New patent filing for AD04 possibly extending market exclusivity to 2045
Alcohol Use Disordersource ↗
◆FDA Feedback ReceivedAD04FiledFDA Meeting
FDA meeting minutes expected within 30 days
Alcohol Use Disordersource ↗
▲Quarterly UpdateCorporate
U.S. Senate Appropriations report encourages FDA to develop alternative endpoints for AUD
▲End Of Phase 2 MeetingAD04FiledFDA Meeting
Successful End of Phase 2 meeting with FDA for AD04
Alcohol Use Disordersource ↗
▲Manufacturing MilestoneAD04FiledCMC / Inspection
Demonstration batches complete; registration and validation batches planned
Alcohol Use Disordersource ↗
▲End Of Phase 2 MeetingAD04FiledFDA Meeting
Successful End of Phase 2 meeting with FDA for AD04
Alcohol Use Disordersource ↗
▲End Of Phase 2 MeetingAD04FiledFDA Meeting
FDA End-of-Phase 2 Meeting held for AD04
Alcohol Use Disordersource ↗
◆Partnership / LicenseAD04FiledCorporate
Strategic partnership discussions expected to accelerate after positive FDA meeting
Alcohol Use Disordersource ↗
◆End Of Phase 2 MeetingAD04FiledFDA Meeting
End of Phase 2 meeting granted by FDA
Alcohol Use Disordersource ↗
▲Quarterly UpdateCorporate
Regained compliance with Nasdaq stockholders' equity listing requirement
▲Patent GrantedAD04FiledIP / Competition
Provisional patent application update filed for AD04
Alcohol Use Disordersource ↗
●Composition Patent FiledAD04FiledIP / Competition
Filed update to provisional patent application for AD04
Alcohol Use Disordersource ↗
Past FDA Catalysts and PDUFA Decisions
How ADIL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2024-12-31 | AD04 (genetically targeted, serotonin-3 receptor antagonist) | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 80%
Micro Cap(rank 526 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AD04 Small moleculeCompletedNCT04101227 | Alcohol Use Disorder | Phase 3 | COMPLETED | 302 | Mar 18, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every ADIL program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| AD04 | Alcohol Use Disorder | Phase 3 | 2026-02-17 | promising results in reducing drinking in heavy drinking patients, and no overt safety or tolerability concernsRead More | Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Coastlands Capital LP10% Owner | Buy | 1,233 388,308 held | $2.75 | 07/16/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ADIL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ADIL for Q2 2026. | ||||
ADIL Institutional Ownership Trends
ADIL Short Interest
Shares sold short, counted twice a month.
7.54%
Short % of Float
of tradable shares sold short
179.6K
Shares Sold Short
-2.0% vs prior count
4.5 Moderate
Days to Cover
trading days of normal volume to buy every short share back
40.2K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ADIL ranks across every disease it competes in
Competitive Position is a premium feature
See how ADIL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialADIL News
ADILAdial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis
Adial Pharmaceuticals has rebranded as Azora Therapeutics, with its stock to trade under the ticker 'AZR'. The company aims to advance AT177, an oral AhR agonist for ulcerative colitis, into Phase 1 trials in 2027. A new executive team has been appointed, bringing extensive experience in drug development. The company has secured approximately $32 million in funding.
Read more →ADIL▼ -6.1%on this newsshared move
Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer
Adial Pharmaceuticals announced that Celia Economides will be appointed as Chief Financial Officer following the approval of certain stockholder proposals. Economides brings over 20 years of experience in biotech finance and has raised more than $1 billion during her career. The company is transitioning to Azora Therapeutics and advancing its lead program, AT177, toward clinical trials.
Read more →ADIL▲ +11.1%on this news· ran to +31% by day 3
Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis
Adial Pharmaceuticals has appointed Dr. David Rubenstein as Chief Scientist to lead the development of AT177, a colon-targeted AhR agonist for ulcerative colitis. Dr. Rubenstein's experience includes overseeing the first FDA-approved AhR agonist, which positions him well for advancing AT177 through IND-enabling studies. The company aims to initiate first-in-human trials by 2027.
Read more →ADILAdial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Adial Pharmaceuticals has announced an inducement stock option grant for a new employee, allowing the purchase of 155,446 shares at an exercise price of $4.22. This grant, approved by the Compensation Committee, is part of the company's strategy to attract talent. Additionally, Adial is progressing with its lead program AT177, aimed at treating ulcerative colitis, with an IND filing expected in early 2027.
Read more →ADIL▲ +25.4%on this news· ran to +48% by day 3
Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update
Adial Pharmaceuticals reported its second quarter financial results for 2026, highlighting the acquisition of Azora Therapeutics and the addition of AT177 to its pipeline, aimed at treating ulcerative colitis. The company secured $32 million in funding to support clinical development. However, it also reported a significant net loss of $52 million, primarily due to merger-related expenses and in-process R&D costs.
Read more →ADIL▼ -10.9%on this news
Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing
Adial Pharmaceuticals has expanded its executive leadership team by appointing Matthew Davidson as chief development officer and Julie Saiki as executive vice president of strategy. The company also announced the successful closing of a $32 million private placement, part of a larger $64 million financing effort, aimed at advancing its lead program, AT177, for ulcerative colitis.
Read more →ADIL▲ +39.9%on this newsshared move
Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing
Adial Pharmaceuticals has acquired Azora Therapeutics, enhancing its pipeline with Azora's lead asset, AT177, aimed at treating ulcerative colitis. The acquisition is coupled with a financing deal worth up to $64 million, which will support the advancement of AT177 through clinical milestones. The company plans to initiate Phase 1 studies in mid-2027, leveraging Azora's innovative approach to minimize systemic exposure.
Read more →ADILAdial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update
Adial Pharmaceuticals reported its first quarter financial results for 2026, highlighting progress in advancing its lead product, AD04, towards late-stage development. The company noted favorable regulatory discussions that could streamline the approval process and reduce costs. Additionally, a collaboration with Molteni Farmaceutici aims to establish a commercial pathway for AD04 in Europe. However, securing funding remains a critical challenge for the company's future plans.
Read more →ADILAdial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045
Adial Pharmaceuticals has filed a new U.S. utility patent application for AD04, its investigational treatment for Alcohol Use Disorder, with expectations to protect its intellectual property through at least 2045. The application includes a Request for Track One Prioritized examination, potentially expediting the patent process. CEO Cary Claiborne highlights this step as crucial for both strengthening the company's asset value and improving its position in licensing negotiations. The company aims to advance AD04 towards its next clinical phase, reflecting a comprehensive approach to its developmental strategy.
Read more →ADILAdial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program
Adial Pharmaceuticals has submitted an application for its AD04 product under the FDA Commissioner's National Priority Voucher Pilot Program. This program is aimed at accelerating the FDA review process for drugs targeting key U.S. health priorities. If granted, the CNPV voucher could reduce review timelines from 10-12 months to 1-2 months, enhancing communication with the FDA. The company is optimistic that this will facilitate quicker approval and market access for AD04, aimed at treating Alcohol Use Disorder among other addictions.
Read more →ADILAdial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial
Adial Pharmaceuticals has successfully completed the demonstration batch production for its investigational drug AD04, which is aimed at treating Alcohol Use Disorder. This milestone allows for the upcoming Phase 3 clinical trial and facilitates necessary regulatory updates with the FDA. The successful technical transfer of manufacturing processes indicates potential efficiencies and compliance with clinical specifications. The company is focused on advancing its development efforts following this achievement and exploring AD04's potential for treating additional addictive disorders.
Read more →ADIL▼ -8.2%on this news
Adial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Therapies for Veterans
Adial Pharmaceuticals has praised the introduction of bipartisan legislation, H.R. 7091, aimed at enhancing research and development of therapies for Alcohol Use Disorder (AUD) among veterans. This legislation acknowledges the high prevalence of AUD in the veteran population and supports non-abstinence based treatment options. Adial's AD04, a genetically targeted therapy, aligns with the updated federal definition of recovery, promoting harm reduction strategies.
Read more →ADIL▼ -7.1%on this news
Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update
Adial Pharmaceuticals reported its financial results for the 2025 fiscal year, highlighting significant progress in regulatory alignment and partnerships. The company received a positive response from the FDA regarding its AD04 product, advancing it towards Phase 3 development. Additionally, Adial secured U.S.-based manufacturing partnerships and expanded its intellectual property portfolio. They also managed to reduce net loss significantly compared to the previous year, which bodes well for financial stability as they pursue new clinical trials and collaborations.
Read more →ADIL▼ -7.3%on this news· ran to -26% by day 3shared move
Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement
Adial Pharmaceuticals has signed a collaboration framework with Molteni Farmaceutici to commercialize AD04 in Europe. The agreement outlines strategic and financial terms, with potential royalties and milestones estimated at nearly $60 million. This partnership marks a significant milestone for Adial as it aims to establish a European market presence for its treatment of Alcohol Use Disorder.
Read more →ADILAdial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement
Adial Pharmaceuticals announced it has regained compliance with Nasdaq's minimum bid price requirement, following a period where its stock price exceeded $1.00 per share. This milestone supports the company's advancement of its lead drug, AD04, towards a pivotal Phase 3 clinical trial for Alcohol Use Disorder. The company is also engaged in strategic partnerships to enhance AD04's development and commercialization.
Read more →ADILAdial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One
Adial Pharmaceuticals has highlighted a recent FDA policy shift that may allow approval of its lead drug candidate, AD04, based on one pivotal trial instead of two. This change could significantly reduce the costs and time associated with Phase 3 trials, enhancing the company's strategic position. The FDA's new direction emphasizes trial quality over quantity, potentially benefiting Adial's development strategy.
Read more →ADIL▼ -5.3%on this news
Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Adial Pharmaceuticals will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026. CEO Cary Claiborne will discuss the company's progress, particularly regarding its investigational drug AD04 for Alcohol Use Disorder. The presentation will be available via webcast, and management will hold one-on-one meetings with investors during the event.
Read more →ADIL▼ -8.9%on this news
Adial Pharmaceuticals Announces Reverse Stock Compliance with Nasdaq's Minimum Bid Price Requirement
Adial Pharmaceuticals has announced a 1-for-25 reverse stock split to comply with Nasdaq's minimum bid price requirement, effective February 5, 2026. This initiative aims to enhance the attractiveness of the company's stock for institutional and retail investors. The company remains focused on advancing its lead investigational treatment, AD04, for Alcohol Use Disorder, and is optimistic about its future strategic priorities. The reverse split will significantly reduce the number of outstanding shares while maintaining shareholder percentages, other than fractional shares.
Read more →ADILAdial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04
Adial Pharmaceuticals has praised a new Congressional directive that encourages the FDA and NIDA to establish alternative clinical trial endpoints for substance use disorders, particularly Alcohol Use Disorder (AUD). This directive aims to include measures like reduced cravings and disorder severity, which align with modern treatment goals. Adial's investigational therapy, AD04, is positioned to benefit from this regulatory evolution, potentially enhancing its development path.
Read more →About Adial Pharmaceuticals, Inc
Headquarters1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA, 22901
Founded2010
BIOPHARMAWATCH ELITE PLUS
Trade the next ADIL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime